Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers

Rabeprazole 10mg b.i.d. is often administered as therapy for eradication of Helicobacter pylori (H. pylori) and is also proposed as therapy for refractory gastro-oesophageal reflux disease. However, there has not been a comprehensive assessment of its acid-suppressive effects. To compare the acid-su...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Digestive and liver disease 2006-11, Vol.38 (11), p.802-808
Hauptverfasser:	Shimatani, T, Moriwaki, M, Xu, J, Tazuma, S, Inoue, M
Format:	Artikel
Sprache:	eng
Schlagworte:	2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage Adult Anti-Ulcer Agents - administration & dosage Aryl Hydrocarbon Hydroxylases - genetics Asian Continental Ancestry Group - genetics Cross-Over Studies Cytochrome P-450 CYP2C19 Dose-Response Relationship, Drug Drug Administration Schedule Gastric Acidity Determination Gastroesophageal Reflux - drug therapy Gastroesophageal Reflux - microbiology Genotype Helicobacter Infections - drug therapy Helicobacter Infections - genetics Helicobacter pylori Humans Hydrogen-Ion Concentration Japan Mixed Function Oxygenases - genetics Pepsinogen A - blood Pepsinogen C - blood Polymorphism, Genetic Prospective Studies Proton-Translocating ATPases - antagonists & inhibitors Rabeprazole Stomach - chemistry
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!